Tranexamic acid (CAS NO. 1197 - 18 - 8) is a well - known antifibrinolytic agent widely used in various medical and cosmetic fields. As a reliable supplier of tranexamic acid, I am delighted to share with you the advantages of this remarkable compound over other antifibrinolytic agents.
1. Pharmacological Mechanism and Specificity
Tranexamic acid exerts its antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin. Plasmin is a proteolytic enzyme that degrades fibrin, the main component of blood clots. By blocking plasminogen activation, tranexamic acid helps to stabilize blood clots and prevent excessive bleeding.
Compared with other antifibrinolytic agents, such as epsilon - aminocaproic acid (EACA), tranexamic acid has a higher affinity for plasminogen. This means that it can more effectively bind to the lysine - binding sites on plasminogen, thereby providing a stronger inhibitory effect on fibrinolysis at lower doses. For example, in a study comparing the two agents in the treatment of postpartum hemorrhage, tranexamic acid was found to be more effective in reducing blood loss with a lower incidence of side effects [1].
2. Efficacy in Different Clinical Settings
- Surgical Procedures: In surgical operations, especially those with a high risk of bleeding, such as cardiac surgery, orthopedic surgery, and dental surgery, tranexamic acid has demonstrated significant advantages. It can reduce intraoperative and postoperative blood loss, thereby decreasing the need for blood transfusions. A meta - analysis of multiple clinical trials showed that the use of tranexamic acid in cardiac surgery led to a 34% reduction in blood transfusion requirements compared to placebo [2]. In contrast, some other antifibrinolytic agents may not provide such a consistent and substantial reduction in blood loss, and their efficacy may vary depending on the surgical procedure and patient characteristics.
- Menorrhagia: Tranexamic acid is also a first - line treatment for menorrhagia, a condition characterized by heavy menstrual bleeding. Clinical studies have shown that it can reduce menstrual blood loss by up to 50% in women with menorrhagia. Other antifibrinolytic agents may have a less pronounced effect on reducing menstrual blood volume or may be associated with more severe side effects, such as gastrointestinal disturbances, which limit their long - term use in this patient population [3].
- Cosmetic Applications: In the cosmetic industry, tranexamic acid is increasingly being used for its skin - lightening properties. It can inhibit the production of melanin by interfering with the activity of tyrosinase, an enzyme involved in melanin synthesis. Compared to some other skin - lightening agents, tranexamic acid is relatively safe and well - tolerated. For instance, hydroquinone, a commonly used skin - lightening agent, can cause skin irritation, allergic reactions, and in some cases, ochronosis, a disfiguring skin condition. Tranexamic acid offers a more gentle alternative for achieving skin brightening without these serious side effects [4].
3. Safety Profile
- Low Toxicity: Tranexamic acid has a favorable safety profile. It is generally well - tolerated by most patients, with a low incidence of serious adverse events. The most common side effects are mild and transient, such as nausea, vomiting, and diarrhea. In contrast, some other antifibrinolytic agents, like aprotinin, were associated with a higher risk of serious side effects, including renal impairment, allergic reactions, and even an increased risk of death in some surgical patients. As a result, aprotinin was withdrawn from the market in many countries [5].
- Few Drug Interactions: Tranexamic acid has relatively few drug interactions. This is an important advantage in clinical practice, as it allows for easier combination with other medications. For example, in patients undergoing surgery, who may be taking multiple drugs for pain management, anesthesia, and prevention of infection, the low potential for drug interactions of tranexamic acid simplifies the treatment process and reduces the risk of adverse drug - drug interactions.
4. Cost - Effectiveness
Tranexamic acid is a cost - effective antifibrinolytic agent. Its relatively low cost makes it accessible for use in a wide range of healthcare settings, especially in developing countries where the availability of expensive medications may be limited. In addition, the reduction in blood transfusion requirements and the shorter hospital stays associated with its use can lead to significant cost savings for healthcare providers and patients. For example, in a study of the economic impact of using tranexamic acid in trauma patients, it was found that the use of this agent resulted in a net cost savings of approximately $1,500 per patient [6].
5. Availability and Stability
As a supplier of tranexamic acid, I can attest to its good availability in the market. It is produced in large quantities and can be easily sourced. Moreover, tranexamic acid is a stable compound. It can be stored at room temperature for an extended period without significant degradation, which is convenient for storage and transportation in healthcare facilities and pharmacies.
In addition to tranexamic acid, we also supply other high - quality cosmetic raw materials, such as Pterostilbene ; CAS NO.:537 - 42 - 8, Beta--Diphosphopyridine Nucleotide(NAD+)Injection Grade, 3 - O - Ethyl - L - ascorbic Acid; CAS NO.: 86404 - 04 - 8, Pro - xylane;CAS NO.439685 - 79 - 7, and Alpha - Glucosyl Hesperidin; CAS NO.: 161713 - 86 - 6.
If you are interested in purchasing tranexamic acid or any of our other products, please feel free to contact us for further details and to discuss your specific requirements. We are committed to providing high - quality products and excellent customer service.
References
[1] Gülmezoglu AM, Carroli G, Duley L, et al. Antifibrinolytic agents for reducing blood loss during delivery. Cochrane Database Syst Rev. 2007; (1):CD001856.
[2] Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high - risk cardiac surgery. N Engl J Med. 2008;358(22):2319 - 2331.
[3] Barlin A, Rosing J, Hoek HC, et al. Tranexamic acid for heavy menstrual bleeding: guideline adherence, prescription trends and historical placebo - controlled efficacy. Thromb Haemost. 2012;108(3):548 - 554.
[4] Choi JH, Yoon DH, Park KY, et al. Efficacy and safety of topical tranexamic acid for the treatment of melasma: a pilot study. Eur J Dermatol. 2013;23(3):344 - 348.
[5] Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354(4):353 - 365.
[6] Cotton BA, Gaither TB, Nunez TC, et al. The economic impact of tranexamic acid use in combat casualties between November 2009 and January 2011. J Trauma Acute Care Surg. 2013;74(3):720 - 727.